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Abstract
Type 1 diabetes mellitus (T1D) is due to autoimmune destruction of pancreatic beta-cells. Previously, we have shown that
intravenously administered bone marrow-derived multipotent mesenchymal stromal cells (MSCs) allows pancreatic islet
recovery, improves insulin secretion and reverts hyperglycemia in low doses streptozotocin (STZ)-induced diabetic mice.
Here we evaluate whether insulin prophylaxis and the administration of a second dose of cells affect the antidiabetic
therapeutic effect of MSC transplantation. Insulitis and subsequent elimination of pancreatic beta-cells was promoted in
C57BL/6 mice by the injection of 40 mg/kg/day STZ for five days. Twenty-four days later, diabetic mice were distributed into
experimental groups according to if they received or not insulin and/or one or two doses of healthy donor-derived MSCs.
Three and half months later: glycemia, pancreatic islets number, insulinemia, glycated hemoglobin level and glucose
tolerance were determined in animals that did not received exogenous insulin for the last 1.5 months. Also, we
characterized MSCs isolated from mice healthy or diabetic. The therapeutic effect of MSC transplantation was observed in
diabetic mice that received or not insulin prophylaxis. Improvements were similar irrespective if they received one or two
doses of cells. Compared to MSCs from healthy mice, MSCs from diabetic mice had the same proliferation and adipogenic
potentials, but were less abundant, with altered immunophenotype and no osteogenic potential. Our preclinical results
should be taken into account when designing phase II clinical trials aimed to evaluate MSC transplantation in patients with
T1D. Cells should be isolated form healthy donor, insulin prophylaxis could be maintained and a second dose, after an
elapse of two months, appears unnecessary in the medium-term.
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Introduction
Diabetes mellitus is a complex metabolic disease with an
estimated worldwide prevalence of 285 million cases in the adult
population [1]. Among these, type 1 diabetes mellitus (T1D)
represents 10% of the diabetic population and its increasing
incidence in developed countries has generated a major global
health issue [2].
T1D results from a cell-mediated autoimmune attack of
pancreatic beta-cells [3]. At the time of clinical diagnosis,
approximately 60% to 80% of the insulin-producing cells have
been destroyed [4]. Standard strategies to care patients with T1D
are based on careful monitoring of food intake and insulin
prophylaxis. Nevertheless, a good metabolic control is difficult to
reach and insulin therapy is frequently associated with severe
episodes of hypoglycemia and hyperglycemia. Thus, even under
treatment, patients with T1D develop severe long-term complica-
tions that clearly reduce their life expectancy [5,6].
It has been shown that pancreatic islet transplantation restores
normoglycemia in patients with T1D [7,8]. However, limited
availability of islet donors, high rates of graft failure and the need
of life-long nonspecific immunosuppressive therapy of the receptor
have been major obstacles to the widespread implementation of
this treatment [9]. Therefore, a therapeutic alternative that can be
broadly used is still needed. Among strategies under development,
those based on stem cells are the most promising [10].
Multipotent mesenchymal stromal cells also referred as to
mesenchymal stem cells (MSCs), is a population of self-renewable
and undifferentiated cells present in several adult tissues [11,12].
They represent an ideal therapeutic tool since they have a great
potential to induce regenerative process [13–15]. MSCs can be
easily isolated from bone marrow aspirates and rapidly expanded
ex vivo [11,16]. Both in vitro and in vivo, they differentiate into cells of
mesodermal origin [11], but also into cells of non-mesodermal
tissues [17–21]. In addition, MSCs can manage exacerbated
immune response and has been reported as hypoimmunogenic
cells, allowing allogeneic transplantation without the requirement
of hystocompatibility, recipient conditioning and/or further
immunosuppresion [15,22]. Bone marrow-derived MSCs have
been used in cell therapy strategies to treat patients with different
diseases, with beneficial effect and without toxicity [23–26]. The
antidiabetic therapeutic effect of MSCs has been tested on the
preclinical models: NOD mice and streptozotocin (STZ)-induced
diabetic murine [27–31]. The transplantation of syngeneic or
allogeneic MSCs, alone or in association with hematopoietic stem
cells, proved to be useful in preventing diabetes onset but also
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intravenous administration of a single dose of 0.5610
6 MSCs to
mice with T1D, results in the reversion of hyperglycemia and
glycosuria [28]. This functional correction was associated with an
increase in the number of pancreatic islets and with the recovery of
the anatomical and numerical distribution of insulin- and
glucagon-producing cells inside them. Thus, MSC transplantation
allows pancreatic islet regeneration [27,28]. Before translating
these promising preclinical data, several practical issues should be
addressed. Here we evaluate whether insulin prophylaxis and the
administration of a second dose of cells affect the antidiabetic
effect of MSC transplantation. Also, we characterized and
compared MSCs isolated from mice healthy or diabetic. The
rationale to test the former is that high-glucose culture conditions
as well as in vivo hyperglycemia have been recognized as critical
factors for the differentiation of adult stem cells into insulin-
producing cells [32,33]. Nonetheless, once diagnosed patients with
T1D receive exogenous insulin to reduce they hyperglycemia. To
our knowledge, nobody has evaluated the impact of MSC
administration in a situation that resembles the stage at which
patients with T1D will be treated, i.e. in normoglycemic diabetic
receptors. By another hand, in the field of MSC transplantation is
a matter of controversy whether multiple doses of cells have any
beneficial impact. Finally, the best source of MSCs for
transplantation is another unresolved issue. Autologous MSCs
appear to be the ideal choice because they minimize infectious
disease dissemination risk. However, chronic diseases could modify
the abundance, the phenotype or the potentials of MSCs.
To evaluate the desired variables, diabetes was induced in
C57BL/6 mice by the administration of 40 mg/kg/day STZ for
five consecutive days [34–36,28]. Twenty-four days later, mice
were randomly distributed into experimental groups according
to if they received or not two timed-release porcine insulin
pellets and/or one or two doses of 0.5610
6 bone marrow-
derived MSCs thathave been exvivo expanded and characterized
according to their expression of surface markers and differen-
tiation potentials (Figure 1). Three and half months after the
interventions: glycemia, pancreatic islet number, insulinemia,
glycated hemoglobin level and glucose tolerance were deter-
mined in animals that did not received exogenous insulin for the
last 1.5 months. Additionally, we characterized and compared
the abundance, immunophenotype, proliferation and differen-
tiation potentials of MSCs obtained from age-matched healthy
and diabetic mice.
Results
Diabetes was induced in C57BL/6 mice by the administration
of five low-doses of STZ. This protocol results in insulitis and in
the destruction of pancreatic beta-cells [37,34,35]. As expected,
animals gradually became hyperglycemic (diabetic, Figure 2)
[28,36], in association with a massive lost of pancreatic islets
Figure 1. Experimental groups. Vehicle A: 0.1 M citrate buffer, pH 4.5. STZ: intraperitoneal 40 mg/kg/day, for five consecutive days. Vehicle B: 5%
mice plasma. MSCs: intravenous 0.5610
6 healthy donor bone marrow-derived MSCs resuspended in 0.2 mL vehicle B. Insulin pellets: subcutaneous
implantation of two timed-release porcine insulin pellets per animal. Triangle represents exogenous insulin levels.
doi:10.1371/journal.pone.0016566.g001
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received or not insulin prophylaxis and/or MSCs (B). Diabetic mice received or not insulin prophylaxis and one or two doses of MSCs (C). Blood
glucose levels were determined every three days in alert nonfasted animals. Data correspond to mean 6 s.e.m. for 9 animals per experimental group.
Only statistical significant values among diabetic mice are shown.
doi:10.1371/journal.pone.0016566.g002
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diabetic mice survived for, at least, four months maintaining their
body weight relatively constant and slightly increasing food and
water intake.
Diabetic mice that received a single dose of MSCs when
hyperglycemic progressively reduced their blood glucose levels
(diabetic + 1xMSCs, Figure 2A). A month after MSC transplanta-
tion, those animals reached near euglycemic values (day 55,
228630 mg/dL) that lasted, at least, for 3.5 months (day 130,
235628 mg/dL). In contrast, untreated diabetic mice remained
hyperglycemic until the end of the study period (day 130,
403622 mg/dL) (diabetic, Figure 2A).
To evaluate whether MSC transplantation could induce the
recovery of pancreatic islets in diabetic mice that were maintained
normoglycemic by insulin prophylaxis, first we determined plasma
exogenous insulin levels in diabetic mice that received subcutane-
ously two timed-release porcine insulin pellets. Exogenous insulin
was found in animal plasma up to 45 days after pellet implantation
(day 5, 29.760.8 mU/L; day 25, 25.460.9 mU/L; day 45,
18.360.8 mU/L); whereas at day 65, pellets were completely
exhausted (not detectable). Accordingly, diabetic mice that
received insulin prophylaxis on day 24 after STZ administration,
six hours after pellet implantation became normoglycemic and
remained in this condition until the exhaustion of the pellets (day
Figure 3. Pancreatic islets recovery, insulin secretion improvement and glycated hemoglobin normalization in diabetic mice after
MSC transplantation. At day 130 after diabetes induction, pancreatic islets were observed (A) and quantified (B) in serial 4 mm hematoxilin/eosin–
stained sections; mouse insulin levels were determined in venous blood samples obtained from alert fasted mice (C); glycated hemoglobin levels
were determined in venous blood samples obtained from alert fasted mice (D). Qualitative data are representative from 4 animals per experimental
group. Quantitative data correspond to mean 6 s.e.m. from 9 animals per experimental group. Only statistical significant values among diabetic mice
are shown.
doi:10.1371/journal.pone.0016566.g003
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animals began to increase their blood glucose levels reaching
hyperglycemic values (day 130, 332620 mg/dL). In contrast,
diabetic mice that received insulin prophylaxis and a single dose of
MSCs remained almost normoglycemic until the end of the study
period (day 130, 175612 mg/dL) (diabetic/insulin + 1xMSCs,
Figure 2B).
We next evaluated whether the reduction of blood glucose level
in diabetic mice transplanted with MSCs could be improved by
the administration of a second dose of cells. For this, diabetic mice
that received a first dose of MSCs under exogenously insulin-
dependent normoglycemic condition were transplanted with a
second dose of MSCs when insulin pellets were exhausted
(Figure 1). No differences were observed in basal glycemic control
between diabetic mice that received one or two doses of MSCs
(day 130, 175612 mg/dL vs. 197623 mg/dL, respectively)
(diabetic/insulin + 1xMSCs vs. diabetic/insulin + 2xMSCs, Figure 2C).
In experimental groups in which sustained hyperglycemia
correction was attained (diabetic + 1xMSCs, diabetic/insulin +
1xMSCs, diabetic/insulin + 2xMSCs) a significant increase in
pancreatic islet number (Figures 3A and B) and an improvement
in endogenous insulin production (Figure 3C) were observed.
Consequently, in the absence of exogenous insulin, diabetic mice
that received MSCs restored their basal level of glycated
hemoglobin (Figure 3D).
We also evaluated whether the recovery of pancreatic islets
promoted by the transplantation of MSCs into diabetic mice
contribute to the maintenance of normoglycemia under a massive
glucose intake. For this, 130 days after diabetes induction mice
were intraperitoneally injected with a high glucose solution and
thereafter blood glucose levels were monitored. Glucose tolerance
was slightly improved in diabetic mice transplanted with MSCs
compared with untreated mice (diabetic + 1xMSCs vs. diabetic,
Figure 4). The observed effect was statistical significant if the
animals received insulin prophylaxis and MSCs (diabetic/insulin +
1xMSCs).
Finally, to approach to the best source of MSCs for
transplantation we characterized cells isolated from mice 90 days
after diabetes induction (diabetic) and compared them with MSCs
obtained from age-matched healthy mice (normal). Viable MSCs
were significantly more abundant in the bone marrow of normal
than in diabetic mice (3163 CFU/million nucleated cells vs.
1662 CFU/million nucleated cells, respectively) (Figure 5A).
MSCs isolated from healthy and diabetic mice did not express
lymphocyte antigens (B220, CD4 and CD8) (Figure 5B). SCA-1
antigen expression did not varied between the cells of those
animals. However, in diabetic mice half of the cells were negative
for CD90 and all of them expressed high levels of CD44
(Figure 5B). MSCs obtained from diabetic mice showed the same
proliferation potential as those obtained from normal mice
(Figure 5C). Additionally, MSCs isolated from healthy mice could
differentiate into both adipocytes and osteocytes, whereas MSCs
obtained from diabetic mice could only differentiate into
adipocytes (Figure 5D, E and F).
Discussion
Despite the best efforts, there has been a steady increase in the
number of patients with T1D worldwide [1]. Up to date, major
goals are the regeneration of pancreatic beta-cells and the
overcome of autoimmunity. In this context, MSC transplantation
represents an interesting therapeutic option due to their potential
to promote regeneration of several tissues and their immunomod-
ulatory properties [13–15,22].
Previously, we and other authors have proven that bone
marrow-derived MSCs given intravenously contribute to the
recovery of pancreatic islets in different diabetic animal models
[27–31]. Nevertheless, before testing this cell therapy in patients
with T1D, it is necessary to evaluate the impact of MSC
transplantation in a situation that closely resembles the clinical
scenario.
It has been proposed that in vitro and in vivo high glucose levels
represent a critical factor for stem cell differentiation into insulin-
Figure 4. Glucose tolerance improvement in diabetic mice after MSC transplantation. At day 130 after diabetes induction, glucose
tolerance was assessed in normal, diabetic, diabetic + 1xMSCs, diabetic/insulin, diabetic/insulin + 1xMSCs and diabetic/insulin + 2xMSCs. Data correspond
to mean 6 s.e.m. for 9 animals per experimental group. p,0.05, diabetic vs. diabetic/insulin + 1xMSC.
doi:10.1371/journal.pone.0016566.g004
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hyperglycemia produced by a 25% glucose injection into non-
diabetic mice is enough to lead to the appearance of insulin-
positive cells in the liver, fat, spleen, bone marrow and thymus
[33]. However, patients with T1D received insulin prophylaxis to
maintain normoglycemia. Using a widely recognized mouse model
of diabetes [34–37] here we demonstrate that, at both hyper- and
normoglycemic conditions, MSC transplantation induces pancre-
atic islet recovery that results in an improvement endogenous
insulin production. Therefore, insulin prophylaxis does not affect
the antidiabetic effect of MSC transplantation; indicating that the
success of this cell therapy strategy is independent of receptor
glucose level. Observed hyperglycemia correction correlates with
the normalization of glycated hemoglobin levels, demonstrating
that MSC transplantation allows the maintenance of blood glucose
at steady levels and prevents episodes of hypoglycemia or severe
hyperglycemia. Furthermore, an improvement in glucose toler-
ance was observed after MSC transplantation. Hence, MSC-
induced pancreatic islet recovery, although incomplete, seems to
be sufficient to regress diabetic mice into a pre-diabetic stage
because they manage blood glucose level properly under a
standard glucose diet but only partially under glucose overload.
The phenotypic corrections here describe were not improved after
the administration, two months later, of a second dose of MSCs.
In animals that received MSCs, we found no solid tumor at the
necropsy. This result was not unexpected, since we transplanted
cells at passage 3 and tumor formation seems to be associated to
the administration of MSCs heavily expanded ex vivo [38].
Up to date, the molecular mechanisms behind the antidiabetic
effect of MSC transplantation have not been unequivocally
proven. The contribution of trophic factors produced by MSCs
[39,40] may be relevant because it has been shown that HGF and
IGF-1 prevent the apoptosis and stimulate the proliferation of
pancreatic beta-cells [41–43]. On the other hand, MSCs can
modulate the immune responses by the release of regulatory
cytokines that inhibit dendritic cells [44], suppress autoreactive T
cells [15] or promote a shift toward a protective Th2 response
[31]. Hence, in diabetic mice the administration of a single dose of
MSCs seems to promote pancreatic islets regeneration and restrict
autoimmunity.
In order to provide evidence supporting the best source of
MSCs for transplantation, we compared the characteristic of cells
obtained from the bone marrow of age-matched healthy animals
with that of diabetic mice. Autologous MSCs are the most
attractive candidate because they are devoid of infectious disease
dissemination risk. It has been proven that MSCs from patient
with T1D can be isolated, expanded and differentiate into insulin-
producing cells [45,46]. Here, we show that viable MSCs obtained
from diabetic mice have the same proliferation and adipogenic
potentials than that of age-matched healthy mice. However, the
abundance, surface marker expression and osteogenic potential
are different between MSCs isolated from diabetic and normal
mice. Accordingly, Stolzing et al. recently demonstrated that the
number of colonies and the osteoblastic differentiation potential of
MSCs isolated from STZ-induced diabetic rats are significantly
reduced compared with that obtained from age-matched healthy
Figure 5. MSCs isolated from diabetic mice are exhausted. MSCs obtained from age-matched healthy mice (normal) or from mice 90 days after
diabetes induction (diabetic) were characterized. Abundance in bone marrow was determined by CFU assay (A). Immunophenotyping was assessed
by flow cytometry analysis after immunostaining with monoclonal antibodies against B220, CD4, CD8, SCA-1, CD90 and CD44 (B). Proliferation kinetic
was evaluated according to crystal violet staining (Absorbance, 570 nm) during 15 days (C). Differentiation potentials were assessed after in vitro
exposure to adipogenic or osteogenic medium and staining with Oil Red or Alizarin Red, respectively (D). Adipocytes generated were stained with
Nile Red and quantified by flow cytometry (E). Matrix mineralization was quantified spectrophotometrically (Absorbance, 405 nm) after Alizarin Red
staining (F). Qualitative data are representative from 4 animals per experimental group. Quantitative data correspond to mean 6 s.e.m. from 4
animals per experimental group. Only statistical significant values are shown.
doi:10.1371/journal.pone.0016566.g005
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diabetic mice exhibit high gene expression level of senescent
(p16
INK4, p66
shc, p53) and apoptotic (Bax, Bak) markers and down-
regulated the expression of survival genes (IGF-1, FGF-2, Akt)
[48]. The differences observed by us between MSCs isolated from
healthy control and diabetic mice seems not to be related to STZ
direct toxicity because: i) the in vivo clearance of STZ is very fast
[49], ii) MSCs isolated seven days after the administration of a
high dose of STZ to rats show the same characteristics of MSCs
isolated from healthy rats [47], iii) we isolated MSCs 90 days after
STZ administration. On the other hand, the observed differences
seems to be related to the diabetic process because: i) Stolzing et al.
reported that at least four weeks of severe hyperglycemia are
necessary to observe some alterations in MSCs [47], ii) most of the
alterations observed in MSCs isolated from diabetic mice could
also be evidenced when MSCs isolated from healthy animals were
incubated in high glucose medium that emulates in vitro a
hyperglycemic condition [48,50], iii) we isolated MSCs from mice
that maintained hyperglycemia higher than 400 mg/dL for most
than two months. Hence, the exhaustion of MSCs observed in our
diabetic mice seems to be related not to STZ treatment but to the
diabetic condition. Considering the altered phenotype of MSCs
isolated from diabetic mice, and the fact that MSCs isolated from
NOD mice were unable to delay diabetic onset [31], we decided
not to evaluate their antidiabetic effect in vivo. Thus, allogeneic
bone marrow seems to be the ideal source of MSCs for
transplantation in patients with T1D, as is the case in the
treatment of patients with other diseases, where promising results
and no toxicity has been described [51,52].
Our preclinical results should be taken into account when
designing phase II clinical trials aimed to evaluate MSC
transplantation in patients with T1D. Cells should be isolated
form healthy donor, insulin prophylaxis could be maintained and
a second dose of MSCs, after an elapse of two months, appears
unnecessary in the medium-term.
Materials and Methods
Animals
C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were
housed at constant temperature and humidity, with a 12:12 hours
light-dark cycle and unrestricted access to a standard diet and
water. When required, animals were lightly anesthetized with
sevofluorane (Abbott, Japan). Animal protocols were approved by
the Ethic Committee of Facultad de Medicina, Clinica Alemana
Universidad del Desarrollo. Approval ID # 010-2008.
Diabetes induction
Eight week-old male C57BL/6 mice were lightly anesthetized.
STZ (Calbiochem, La Jolla, CA) was dissolved in vehicle A (0.1 M
citrate buffer, pH 4.5), and immediately injected intraperitoneally
at a dose of 40 mg/kg/day, for five consecutive days [28].
Blood glucose determination and diabetes diagnostic
criteria
From non-fasted alert animals, blood samples were collected
from the tail vein and glucose levels were determined with the
glucometer system Accu-Chek Go from Roche Diagnostic (Mann-
heim, Germany). Mice were considered diabetic if blood glucose
levels were above 250 mg/dL, on three consecutive determinations.
MSC isolation and ex vivo expansion
Six to eight week-old C57BL/6 mice were sacrificed. Bone
marrow cells were obtained by flushing femurs and tibias with
sterile PBS. After centrifugation, cells were resuspended in alpha-
MEM (Gibco, Auckland, NZ) supplemented with 10% selected
fetal bovine serum (Gibco, Auckland, NZ) and 80 mg/mL
gentamicin (Sanderson Laboratory, Chile) (alpha-10) and plated
at a density of 1610
6 nucleated cells/cm
2. Non-adherent cells
were removed after 72 hours by media change. When foci reach
confluence, adherent cells were detached with 0.25% trypsin,
2.65 mM EDTA (Gibco, Auckland, NZ), centrifuged and
subcultured at 7,000 cells/cm
2. After two subcultures, adherent
cells were characterized and transplanted.
MSC characterization
CFU assay: Bone marrow cells were resuspended in alpha-10
and plated at a density of 17,000 nucleated cells/cm
2 in triplicate.
Non-adherent cells were removed by media change twice a week.
At day 21, cells were fixed with 4% paraformaldehyde for 10
minutes and stained with 0.5% crystal violet (Sigma-Aldrich, St.
Louis, MO) in 10% methanol for 20 minutes. After four washes,
colonies formed by more than 30 fibroblast-like cells were counted
under light microscope at low magnification. Results were
expressed as CFU/million of nucleated cells plated.
Immunophenotyping. Although there are currently no
consensus markers for murine MSCs as there exist for human
MSCs [12], immunophenotyping was performed by flow
cytometry analysis after immunostaining with monoclonal
antibodies against lymphocyte markers B220, CD4, CD8 (PE-
Cy5-conjugated, BD Pharmingen, San Jose, CA) and putative
murine MSC markers SCA-1 (APC-conjugated), CD90 (PE-
conjugated) and CD44 (PE-Cy5-conjugated) (all from eBioscience,
San Diego, CA).
Proliferation assay. First passaged MSCs were subcultured
at 4,000 cells/cm
2. Media was changed every three days. Cell
number was determined at days 0, 2, 5, 7, 9, 12 and 15 after
staining with 0.5% crystal violet in 10% methanol for 20 minutes.
After four washes, cell-incorporated crystal violet was solubilized
by incubation with phosphate buffer in methanol (50:50) and
quantified spectrophotometrically (absorbance, 570 nm).
Differentiation assays. MSCs were incubated with
standard adipogenic or osteogenic differentiation media for 14
and 21 days, respectively [53]. To quantify the adipogenic
potential, cultures were stained with 1 mg/mL Nile Red (Sigma-
Aldrich, St. Louis, MO) and analyzed by flow cytometry [54]. To
quantify the osteogenic potential, cultures were fixed with 10%
formaldehyde and stained with 40 mM Alizarin Red (Sigma-
Aldrich, St. Louis, MO). After four washes, Alizarin Red stain was
solubilized with 10% acetic acid neutralized with 10% ammonium
hydroxide and quantified spectrophotometrically (absorbance,
405 nm) [55].
MSC transplantation
0.5610
6 MSCs were resuspended in 0.2 mL of vehicle B (5%
mice plasma) and administered via the tail vein to lightly
anesthetized mice.
Insulin prophylaxis
Twenty-four days post-diabetes induction, two timed-release
porcine insulin pellets (Linbit, Linshine, Canada) were implanted
subcutaneously, following manufacturer instructions, to lightly
anesthetized mice.
Pancreas histology
Mice were sacrificed by cervical dislocation. Pancreas were
rapidly removed, fixed in 4% paraformaldehyde and embedded in
Insulin Prophylaxis & 2nd Dose Unaffect MSC Effect
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ilin-eosin (Sigma-Aldrich, St. Louis, MO). Slices were analyzed
under light microscopy, focusing on pancreatic islets. Images were
captured with a digital camera.
Plasma insulin determination
Plasma insulin was assayed on blood samples collected from the
tail vein of fasted alert animals using mouse or porcine insulin
ultrasensitive ELISA kits (Mercodia, Uppsala, Sweden). Kit
reagents guarantee no cross-reactivity between those insulins.
Glycated hemoglobin determination
HbA1c was assayed on blood samples collected from the tail vein
of fasted alert animals using DCA2000 analyzer (Bayer Corpora-
tion, Elkhart, IN) [56].
Intraperitoneal glucose tolerance test
After six hours of fasting, mice were lightly anesthetized and
injected intraperitoneally with 2 mg glucose/g body weight. Blood
glucose levels were determined 15 minutes before and 15, 30, 60,
90, 120 and 150 minutes after glucose administration. Area under
the curve was determined by the trapezoidal rule.
Statistical analysis
Data shown correspond to all animal studied and were
represented as mean6s.e.m. Multiple group comparisons were
performed by ANOVA followed by Bonferroni post-hoc test.
p,0.05 were considered statistically significant.
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